Fibrocell Science, Inc. to Present at the 5th Annual OneMedForum San Francisco 2012

EXTON, Pa.--(BUSINESS WIRE)-- Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will be presenting at the 5th Annual OneMedForum San Francisco 2012 to be held on January 9-12 at The Sir Francis Drake Hotel.

Fibrocell’s presentation is scheduled for Wednesday, January 11, 2012 at 10:00 AM Pacific Time.

The presentation will be webcast live, and a replay will be available during the week of January 9 at www.onemedplace.com.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (OTCBB: FCSC) is a biotechnology company focused on the development of regenerative cell therapy for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.



CONTACT:

Media
Marina Maher Communications
Jessica Morrison
212-485-6806
[email protected]
or
Investors
ICR, LLC
Sherry Bertner
Managing Director
646-277-1247
[email protected]

KEYWORDS:   United States  North America  California  Pennsylvania

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  Research  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.